Nycomed

FUJIFILM Diosynth Biotechnologies President and CEO Lars Petersen appoints Dennis Schmidt Pedersen as Chief People Officer

Retrieved on: 
Monday, October 2, 2023

Hillerød, Denmark, Oct. 02, 2023 (GLOBE NEWSWIRE) -- FUJIFILM Diosynth Biotechnologies President and CEO Lars Petersen today announced a new strategic leadership appointment to support the company through its next growth phase.

Key Points: 
  • Hillerød, Denmark, Oct. 02, 2023 (GLOBE NEWSWIRE) -- FUJIFILM Diosynth Biotechnologies President and CEO Lars Petersen today announced a new strategic leadership appointment to support the company through its next growth phase.
  • Dennis Schmidt Pedersen will serve as Chief People Officer (CPO) effective immediately.
  • Schmidt Pedersen will report to President and CEO Lars Petersen and will serve as a member of the executive leadership team, leading the company's global people and culture team.
  • “We are delighted to welcome Dennis Schmidt Pedersen to FUJIFILM Diosynth Biotechnologies,” said Lars Petersen, president and chief executive officer, FUJFILM Diosynth Biotechnologies.

Intrommune Expands and Strengthens Senior Leadership Team

Retrieved on: 
Wednesday, September 28, 2022

NEW YORK, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced the appointment of Stuart Loesch as President and Dr. William Berger as Head of Clinical Development.

Key Points: 
  • Prior to joining Intrommune in August of 2021, Loesch gained a deep understanding of allergy immunotherapy as Vice President of Marketing, BD and Commercial Strategy at ALK.
  • He has also held several leadership roles within several societies and organizations, including past president of the American College of Allergy, Asthma & Immunology.
  • "I feel truly privileged to be part of a superb team here at Intrommune that is dedicated to developing safe and effective therapies for individuals suffering from food allergies.
  • Im excited to welcome Dr. Berger to Intrommune and look forward to working with him in this new role.

Worldwide Clinical Trials Appoints Barry Lederman as Chief Financial Officer

Retrieved on: 
Wednesday, August 31, 2022

Worldwide Clinical Trials (Worldwide), the industrys leading global, midsize, full-service contract research organization (CRO), has announced the appointment of Barry Lederman as Chief Financial Officer (CFO) to lead its finance, accounting, and legal functions.

Key Points: 
  • Worldwide Clinical Trials (Worldwide), the industrys leading global, midsize, full-service contract research organization (CRO), has announced the appointment of Barry Lederman as Chief Financial Officer (CFO) to lead its finance, accounting, and legal functions.
  • View the full release here: https://www.businesswire.com/news/home/20220831005142/en/
    Worldwide Clinical Trials appoints Barry Lederman as CFO.
  • Barry is well-recognized and respected for his proven track record of growing and improving companies throughout his 20+ year career, said Peter Benton , President and Co-CEO, Worldwide.
  • Worldwide Clinical Trials is a global, midsize contract research organization (CRO) that provides top-performing bioanalytical and Phase I-IV clinical development services to the biotechnology and pharmaceutical industries.

Ceapro Bolsters Executive Management Team with Appointment of Sigrun Watson as Chief Revenue Officer

Retrieved on: 
Tuesday, July 12, 2022

EDMONTON, Alberta, July 12, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the appointment of Sigrun Watson as its Chief Revenue Officer, responsible for corporate strategy development and execution across the Cosmeceutical and personal care brand business, as well as Ceapro’s expansion into the Nutraceutical and Pharmaceutical markets.

Key Points: 
  • Gilles Gagnon, President and Chief Executive Officer of Ceapro commented, We are incredibly pleased to welcome Sigrun to the Ceapro management team.
  • We look forward to leveraging her knowledge and expertise as we execute on our initiatives moving forward to propel Ceapro to its next phase of growth.
  • Ceapro has laid a solid foundation in its Cosmeceutical business sector and has positioned itself for significant growth across the Nutraceutical and Pharmaceutical markets.
  • Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals.

Intravacc publishes 2021 annual report and announces expansion of its management team and board of directors

Retrieved on: 
Tuesday, July 5, 2022

In addition, Intravacc's Chief Financial Officer Nathalie Laarakker has been appointed to the board of directors.

Key Points: 
  • In addition, Intravacc's Chief Financial Officer Nathalie Laarakker has been appointed to the board of directors.
  • The annual report for the financial year 2021, including a review of figure, performance and Financial Statements for the Year ended 31 December 2021, is available online here and can also be downloaded as PDF.
  • A summary of Intravacc's financials are also published in the Annual Report Management of State Participations 2021 ( page 165-168, in Dutch ).
  • Furthermore, Intravacc B.V. is very pleased with the expansion of its management team and board of directors.

Intravacc publishes 2021 annual report and announces expansion of its management team and board of directors

Retrieved on: 
Tuesday, July 5, 2022

In addition, Intravacc's Chief Financial Officer Nathalie Laarakker has been appointed to the board of directors.

Key Points: 
  • In addition, Intravacc's Chief Financial Officer Nathalie Laarakker has been appointed to the board of directors.
  • The annual report for the financial year 2021, including a review of figure, performance and Financial Statements for the Year ended 31 December 2021, is available online here and can also be downloaded as PDF.
  • A summary of Intravacc's financials are also published in the Annual Report Management of State Participations 2021 ( page 165-168, in Dutch ).
  • Furthermore, Intravacc B.V. is very pleased with the expansion of its management team and board of directors.

EXACT Therapeutics AS Announces Appointment of Dr Per Walday as Chief Executive Officer

Retrieved on: 
Monday, March 28, 2022

OSLO, Norway and LONDON, March 28, 2022 /PRNewswire/ -- EXACT Therapeutics AS ("EXACT-Tx", Euronext Growth: EXTX), a clinical stage precision health company utilising Acoustic Cluster Therapy (ACT) across multiple therapeutic areas, announces that its Board of Directors has today appointed Dr Per Walday as Chief Executive Officer (CEO).

Key Points: 
  • OSLO, Norway and LONDON, March 28, 2022 /PRNewswire/ -- EXACT Therapeutics AS ("EXACT-Tx", Euronext Growth: EXTX), a clinical stage precision health company utilising Acoustic Cluster Therapy (ACT) across multiple therapeutic areas, announces that its Board of Directors has today appointed Dr Per Walday as Chief Executive Officer (CEO).
  • Dr Per Walday, Chief Executive Officer-designate of EXACT-Tx, said: "I am very excited to be joining EXACT-Tx and very impressed by the potential of its proprietary technology.
  • In his most recent role, Dr Walday served as Chief Executive officer of PCI Biotech.
  • It was during his time at GE Healthcare that Dr. Walday worked alongside the founders of EXACT Therapeutics and some of the Board members.

EXACT Therapeutics AS Announces Appointment of Dr Per Walday as Chief Executive Officer

Retrieved on: 
Monday, March 28, 2022

OSLO, Norway and LONDON, March 28, 2022 /PRNewswire/ -- EXACT Therapeutics AS ("EXACT-Tx", Euronext Growth: EXTX), a clinical stage precision health company utilising Acoustic Cluster Therapy (ACT) across multiple therapeutic areas, announces that its Board of Directors has today appointed Dr Per Walday as Chief Executive Officer (CEO).

Key Points: 
  • OSLO, Norway and LONDON, March 28, 2022 /PRNewswire/ -- EXACT Therapeutics AS ("EXACT-Tx", Euronext Growth: EXTX), a clinical stage precision health company utilising Acoustic Cluster Therapy (ACT) across multiple therapeutic areas, announces that its Board of Directors has today appointed Dr Per Walday as Chief Executive Officer (CEO).
  • Dr Per Walday, Chief Executive Officer-designate of EXACT-Tx, said: "I am very excited to be joining EXACT-Tx and very impressed by the potential of its proprietary technology.
  • In his most recent role, Dr Walday served as Chief Executive officer of PCI Biotech.
  • It was during his time at GE Healthcare that Dr. Walday worked alongside the founders of EXACT Therapeutics and some of the Board members.

Sobi continues the R&D transformation - Anders Ullman appointed new Head of R&D

Retrieved on: 
Monday, December 13, 2021

In support of the transformation, Dr Ullman will be based in Basel, Switzerland, report to CEO Guido Oelkers and become a member of the Sobi Executive Committee.

Key Points: 
  • In support of the transformation, Dr Ullman will be based in Basel, Switzerland, report to CEO Guido Oelkers and become a member of the Sobi Executive Committee.
  • Guido Oelkers: "We welcome Anders in his new capacity having served in 2021 on the Sobi Board of Directors.
  • Dr Ullman will leave the Sobi Board of Directors as a result of the management appointment.
  • In 2015, Dr Ullman returned to academia to head up a pulmonology unit at the Sahlgrenska University Hospital in Gothenburg, Sweden.

Sobi continues the R&D transformation - Anders Ullman appointed new Head of R&D

Retrieved on: 
Monday, December 13, 2021

In support of the transformation, Dr Ullman will be based in Basel, Switzerland, report to CEO Guido Oelkers and become a member of the Sobi Executive Committee.

Key Points: 
  • In support of the transformation, Dr Ullman will be based in Basel, Switzerland, report to CEO Guido Oelkers and become a member of the Sobi Executive Committee.
  • Guido Oelkers: "We welcome Anders in his new capacity having served in 2021 on the Sobi Board of Directors.
  • Dr Ullman will leave the Sobi Board of Directors as a result of the management appointment.
  • In 2015, Dr Ullman returned to academia to head up a pulmonology unit at the Sahlgrenska University Hospital in Gothenburg, Sweden.